Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma

Inclusion Criteria: * Male or female ≥18 years of age. * Histologically or cytologically confirmed stage IV, metastatic squamous or non-squamous NSCLC that has progressed after a platinum-based chemotherapy and after a single-agent immunotherapy OR histologically or cytologically confirmed metastatic uveal melanoma that is immunotherapy naive * Evaluable or measurable disease as per RECIST 1:1, a target lesion of suitable diameter (at least 5 mm) for SBRT, and a non-target lesion of at least 1 cm in diameter for abscopal effect evaluation. * ≥ 4 weeks since any major surgery. * A 2-week washout period post any prior systemic anticancer therapy, RT, and/or investigational therapy is required prior to trial entry. Subject should be adequately recovered from the acute toxicities of any prior therapy. * Life expectancy greater than or equal to 6 months. * Eastern Cooperative Oncology Group performance status of 0-1. * Adequate bone marrow function: * Absolute neutrophil count ≥ 1.5 x 10\^9/L (without granulocyte colony stimulating factor support within 2 weeks of laboratory test used to determine eligibility) * Platelets ≥ 100 x 10\^9/L (without transfusion within 2 weeks of laboratory test used to determine eligibility) * Hemoglobin ≥ 8 g/dL (without blood transfusion) * White blood cell count \> 2,500/uL and \< 15,000/uL * Lymphocyte count ≥ 500/uL * Adequate liver function (NSLC Cohort): * Serum bilirubin less than or equal to 1.0 X upper limit of normal (ULN; p…